Jaskaran Singh
Research scientist at Janssen Research and Development (Johnson & Johnson Innovative Medicine)
Data updated
Papers
Trials
Research Footprint
Jaskaran Singh appears in 5 tracked papers (2016–2022), most studied alongside Ketamine, Esketamine and Placebo, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Safety & Risk Management.
Most-cited paper: A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression (526 citations).
Frequent co-authors: Ella Daly, William Drevets and Ibrahim Turkoz.
Background & Research
Jaskaran B. Singh is a pharmaceutical industry researcher whose published work centers on rapid-acting antidepressant treatments, especially ketamine and esketamine, for treatment-resistant depression. A PubMed record for the 2016 randomized ketamine dose-frequency study lists him as the first author and places him at Janssen Research and Development. His later work also appears on analyses of dissociation, adverse events, and antidepressant response in esketamine trials.
Key Impact
He is a key industry researcher on ketamine/esketamine trials for treatment-resistant depression, including pivotal studies that helped characterize antidepressant efficacy, dosing, and dissociation safety.
Collaboration Network
10 collaborators· click a node to visit their profile
Full network →Compounds
Topics
Top Collaborators
Affiliations
Institutions, companies, and organisations Jaskaran Singh is associated with.
Janssen Research & Development
pharmaJanssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.
View stakeholder →Johnson & Johnson
Big PharmaJohnson & Johnson is a publicly traded global healthcare company rather than a venture fund or dedicated asset manager. Its business spans pharmaceuticals and medical technology, and the company is based in New Brunswick, New Jersey, United States. In the psychedelic ecosystem, Johnson & Johnson matters mainly through its neuroscience and psychiatry-adjacent pharmaceutical activity rather than as a standalone investor. Its acquisition of Intra-Cellular Therapies, a CNS-focused biopharma, shows continued interest in neuropsychiatric therapeutics and related clinical-stage assets.
View stakeholder →